Kartos Therapeutics
Kartos Therapeutics is a clinical stage biopharmaceutical company with a potential best-in-class MDM2 inhibitor (KRT-232) in clinical development, across a variety of TP53 wild-type hematological malignancies and solid tumors.
Last updated on
About Kartos Therapeutics
Founded
2018Estimated Revenue
$1M-$10MEmployees
51-250Category
Industry
BiotechnologyLocation
City
Redwood CityState
CaliforniaCountry
United StatesKartos Therapeutics
Find your buyer within Kartos Therapeutics